The Centers for Disease Control and Prevention (CDC) has recently issued a recommendation for the use of a new injection developed by Sanofi and AstraZeneca to prevent respiratory syncytial virus (RSV) in newborns. This marks the latest effort in the fight against RSV this fall.
Following a meeting of an expert advisory committee, the CDC announced on Thursday that it now recommends routine use of this new medicine in babies younger than eight months old. The committee voted unanimously in favor of supporting the use of the injection.
This recommendation comes as no surprise to investors, as Sanofi’s stock saw a 1.1% increase in early trading, while AstraZeneca’s stock experienced a slight decrease of 0.2% in response to the news.
RSV is a common ailment that can pose serious health risks, particularly in newborns and older adults. Pfizer and GSK are also launching RSV vaccines for older adults this fall. However, the CDC’s endorsement of these vaccines was not as enthusiastic. It stated that adults aged 60 and above “may receive” the shots if it is deemed appropriate by them and their physicians.
In contrast, the CDC’s endorsement of the Sanofi and AstraZeneca injection, called Beyfortus, was wholehearted. The agency now recommends administering Beyfortus to all infants younger than eight months either upon birth or during their first RSV season, which typically spans from fall to spring.
Additionally, the CDC suggests that children aged 8 to 19 months who are at high risk of severe RSV disease receive a second dose of Beyfortus as they enter their second RSV season.
It is important to note that Beyfortus is not a vaccine but rather a monoclonal antibody medication. Unlike a vaccine, which stimulates the immune system to produce antibodies to fight off an RSV infection, Beyfortus directly provides these antibodies. It is administered through an injection.
The CDC has reported that Beyfortus has been successful in reducing the risk of hospitalizations and healthcare visits due to RSV by approximately 80%.
The Food and Drug Administration granted approval for Beyfortus in mid-July. Sanofi has confirmed that the medication will be available in time for this year’s RSV season.
